Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Sell
35
AXSM Quote, Financials, Valuation and Earnings
Last price:
$97.97
Seasonality move
:
29%
Day range:
$93.95 - $98.46
52-week range:
$64.11 - $139.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.18x
P/B ratio:
83.87x
Volume:
868.3K
Avg. volume:
775.6K
1-year change:
36.71%
Market cap:
$4.8B
Revenue:
$385.7M
EPS (TTM):
-$5.99
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics
|
$121.1M | -$1.30 | 61.86% | -6.01% | $173.89 |
|
ALNY
Alnylam Pharmaceuticals
|
$586.2M | -$0.34 | 20.07% | -15.81% | $313.97 |
|
BBIO
BridgeBio Pharma
|
$59.1M | -$0.86 | -72.93% | -330% | $53.82 |
|
BIIB
Biogen
|
$2.2B | $3.45 | -5.6% | 2.34% | $197.16 |
|
BIVI
BioVie
|
-- | -$0.32 | -- | -41.86% | $5.50 |
|
IART
Integra Lifesciences Holdings
|
$381.2M | $0.43 | 3.33% | 241.78% | $24.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics
|
$98.06 | $173.89 | $4.8B | -- | $0.00 | 0% | 12.18x |
|
ALNY
Alnylam Pharmaceuticals
|
$237.77 | $313.97 | $30.8B | -- | $0.00 | 0% | 13.50x |
|
BBIO
BridgeBio Pharma
|
$33.91 | $53.82 | $6.4B | -- | $0.00 | 0% | 28.43x |
|
BIIB
Biogen
|
$115.17 | $197.16 | $16.9B | 10.29x | $0.00 | 0% | 1.74x |
|
BIVI
BioVie
|
$0.78 | $5.50 | $14.4M | -- | $0.00 | 0% | -- |
|
IART
Integra Lifesciences Holdings
|
$16.99 | $24.75 | $1.3B | 70.14x | $0.00 | 0% | 0.81x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AXSM
Axsome Therapeutics
|
76.02% | 1.663 | 4.39% | 1.99x |
|
ALNY
Alnylam Pharmaceuticals
|
93.86% | 1.604 | 3.37% | 2.61x |
|
BBIO
BridgeBio Pharma
|
679.11% | 1.682 | 32.94% | 4.44x |
|
BIIB
Biogen
|
27.36% | 0.095 | 28.25% | 0.77x |
|
BIVI
BioVie
|
-- | -0.693 | -- | -- |
|
IART
Integra Lifesciences Holdings
|
53.85% | 2.157 | 103.03% | 0.59x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics
|
$108.3M | -$61.6M | -96.73% | -244.32% | -61.14% | -$26.2M |
|
ALNY
Alnylam Pharmaceuticals
|
$490.3M | -$105.2M | -29.16% | -- | -26.13% | -$103.8M |
|
BBIO
BridgeBio Pharma
|
$3.8M | -$221.3M | -108.74% | -- | -4019.3% | -$198.6M |
|
BIIB
Biogen
|
$1.9B | $450.6M | 7.33% | 10.33% | 14.32% | $694.6M |
|
BIVI
BioVie
|
-- | -$7.3M | -- | -- | -- | -$8.6M |
|
IART
Integra Lifesciences Holdings
|
$249.1M | $35.6M | -0.21% | -0.45% | 9.38% | $11.2M |
Axsome Therapeutics vs. Competitors
-
Which has Higher Returns AXSM or ALNY?
Alnylam Pharmaceuticals has a net margin of -63.08% compared to Axsome Therapeutics's net margin of -14.12%. Axsome Therapeutics's return on equity of -244.32% beat Alnylam Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics91.15% -$1.54 $237.7M ALNYAlnylam Pharmaceuticals82.67% -$0.65 $1.1B -
What do Analysts Say About AXSM or ALNY?
Axsome Therapeutics has a consensus price target of $173.89, signalling upside risk potential of 77.33%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $313.97 which suggests that it could grow by 32.05%. Given that Axsome Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Axsome Therapeutics is more attractive than Alnylam Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics13 0 0 ALNYAlnylam Pharmaceuticals12 8 1 -
Is AXSM or ALNY More Risky?
Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.047%.
-
Which is a Better Dividend Stock AXSM or ALNY?
Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or ALNY?
Axsome Therapeutics quarterly revenues are $118.8M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Axsome Therapeutics's net income of -$74.9M is higher than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.18x versus 13.50x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics12.18x -- $118.8M -$74.9M ALNYAlnylam Pharmaceuticals13.50x -- $593.2M -$83.8M
-
Which has Higher Returns AXSM or BBIO?
BridgeBio Pharma has a net margin of -63.08% compared to Axsome Therapeutics's net margin of -4506.12%. Axsome Therapeutics's return on equity of -244.32% beat BridgeBio Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics91.15% -$1.54 $237.7M BBIOBridgeBio Pharma64.57% -$1.40 $263.8M -
What do Analysts Say About AXSM or BBIO?
Axsome Therapeutics has a consensus price target of $173.89, signalling upside risk potential of 77.33%. On the other hand BridgeBio Pharma has an analysts' consensus of $53.82 which suggests that it could grow by 58.73%. Given that Axsome Therapeutics has higher upside potential than BridgeBio Pharma, analysts believe Axsome Therapeutics is more attractive than BridgeBio Pharma.
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics13 0 0 BBIOBridgeBio Pharma10 3 0 -
Is AXSM or BBIO More Risky?
Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.078, suggesting its more volatile than the S&P 500 by 7.822%.
-
Which is a Better Dividend Stock AXSM or BBIO?
Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or BBIO?
Axsome Therapeutics quarterly revenues are $118.8M, which are larger than BridgeBio Pharma quarterly revenues of $5.9M. Axsome Therapeutics's net income of -$74.9M is higher than BridgeBio Pharma's net income of -$265.1M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.18x versus 28.43x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics12.18x -- $118.8M -$74.9M BBIOBridgeBio Pharma28.43x -- $5.9M -$265.1M
-
Which has Higher Returns AXSM or BIIB?
Biogen has a net margin of -63.08% compared to Axsome Therapeutics's net margin of 10.87%. Axsome Therapeutics's return on equity of -244.32% beat Biogen's return on equity of 10.33%.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics91.15% -$1.54 $237.7M BIIBBiogen76.23% $1.83 $23B -
What do Analysts Say About AXSM or BIIB?
Axsome Therapeutics has a consensus price target of $173.89, signalling upside risk potential of 77.33%. On the other hand Biogen has an analysts' consensus of $197.16 which suggests that it could grow by 71.19%. Given that Axsome Therapeutics has higher upside potential than Biogen, analysts believe Axsome Therapeutics is more attractive than Biogen.
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics13 0 0 BIIBBiogen12 18 0 -
Is AXSM or BIIB More Risky?
Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.
-
Which is a Better Dividend Stock AXSM or BIIB?
Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or BIIB?
Axsome Therapeutics quarterly revenues are $118.8M, which are smaller than Biogen quarterly revenues of $2.5B. Axsome Therapeutics's net income of -$74.9M is lower than Biogen's net income of $266.7M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 10.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.18x versus 1.74x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics12.18x -- $118.8M -$74.9M BIIBBiogen1.74x 10.29x $2.5B $266.7M
-
Which has Higher Returns AXSM or BIVI?
BioVie has a net margin of -63.08% compared to Axsome Therapeutics's net margin of --. Axsome Therapeutics's return on equity of -244.32% beat BioVie's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics91.15% -$1.54 $237.7M BIVIBioVie-- -$0.46 -- -
What do Analysts Say About AXSM or BIVI?
Axsome Therapeutics has a consensus price target of $173.89, signalling upside risk potential of 77.33%. On the other hand BioVie has an analysts' consensus of $5.50 which suggests that it could grow by 605.13%. Given that BioVie has higher upside potential than Axsome Therapeutics, analysts believe BioVie is more attractive than Axsome Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics13 0 0 BIVIBioVie2 0 0 -
Is AXSM or BIVI More Risky?
Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison BioVie has a beta of 1.270, suggesting its more volatile than the S&P 500 by 26.987%.
-
Which is a Better Dividend Stock AXSM or BIVI?
Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioVie offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. BioVie pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or BIVI?
Axsome Therapeutics quarterly revenues are $118.8M, which are larger than BioVie quarterly revenues of --. Axsome Therapeutics's net income of -$74.9M is lower than BioVie's net income of -$7.1M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while BioVie's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.18x versus -- for BioVie. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics12.18x -- $118.8M -$74.9M BIVIBioVie-- -- -- -$7.1M
-
Which has Higher Returns AXSM or IART?
Integra Lifesciences Holdings has a net margin of -63.08% compared to Axsome Therapeutics's net margin of 4.39%. Axsome Therapeutics's return on equity of -244.32% beat Integra Lifesciences Holdings's return on equity of -0.45%.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics91.15% -$1.54 $237.7M IARTIntegra Lifesciences Holdings56.27% $0.25 $3.3B -
What do Analysts Say About AXSM or IART?
Axsome Therapeutics has a consensus price target of $173.89, signalling upside risk potential of 77.33%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $24.75 which suggests that it could grow by 45.67%. Given that Axsome Therapeutics has higher upside potential than Integra Lifesciences Holdings, analysts believe Axsome Therapeutics is more attractive than Integra Lifesciences Holdings.
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics13 0 0 IARTIntegra Lifesciences Holdings2 5 2 -
Is AXSM or IART More Risky?
Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.241, suggesting its more volatile than the S&P 500 by 24.12%.
-
Which is a Better Dividend Stock AXSM or IART?
Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or IART?
Axsome Therapeutics quarterly revenues are $118.8M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $442.6M. Axsome Therapeutics's net income of -$74.9M is lower than Integra Lifesciences Holdings's net income of $19.4M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.18x versus 0.81x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics12.18x -- $118.8M -$74.9M IARTIntegra Lifesciences Holdings0.81x 70.14x $442.6M $19.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Bloom Energy Stock a Buy, Sell or Hold?
While already interesting as the world moves toward greener energy…
What Do Tesla Delivery Numbers Mean for Tesla Stock?
Tesla (NASDAQ:TSLA) released Q1 delivery numbers, showing a substantial slowdown…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
